XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops monoclonal antibodies for treating a variety of diseases, such as cancer, vascular disease, inflammatory skin disease, and diabetes.

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Xbiotech Inc (XBIT US)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-06-20)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Annual Report to Security Holders (Form ARS | Period ending 2023-12-31)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)